What are the benefits of prasugrel relative to clopidogrel in STEMI?
The benefits of prasugrel relative to clopidogrel in STEMI include a lower 30-day rate of the composite primary outcome and a significantly lower rate of stent thrombosis reported at 30 days. In addition, prasugrel achieves greater inhibition of platelet aggregation than clopidogrel. However, it must be weighed against the increased risk of bleeding associated with its use.